The European Commission has approved Zejula (niraparib) as a first-line maintenance therapy for people with advanced ovarian, fallopian tube, or primary peritoneal cancer, who respond to platinum-based chemotherapy. This decision follows a positive recommendation issued by the Committee for Medicinal Products for Human Use (CHMP), a branch of the European Medicines Agency (EMA). Zejula is now the first PARP inhibitor to be approved in Europe as a stand-alone therapy for women with advanced ovarian cancer, regardless…
You must be logged in to read/download the full post.
The post Zejula Approved in Europe as Maintenance Therapy for Advanced Ovarian Cancers appeared first on BioNewsFeeds.